HKHenry Koziel

Henry Koziel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Henry Koziel has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Robert Garland

    2 shared publications
  • Xiuhong Li

    Division of Pulmonary and Critical Care Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts; and MacArthur Center for Molecular Parasitology, Yale University School of Medicine, New Haven, Connecticut

    2 shared publications
  • Christine Reardon

    Divisions of Pulmonary and Critical Care Medicine, Departments of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston; and Division of Pulmonary and Critical Care, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts

    1 shared publication
  • David Delaney

    1 shared publication
  • Frank F. Richards

    Division of Pulmonary and Critical Care Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts; and MacArthur Center for Molecular Parasitology, Yale University School of Medicine, New Haven, Connecticut

    1 shared publication
  • Geoffrey S. Gilmartin

    Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

    1 shared publication

Latest Publications

  • Pneumocystis Carinii Pneumonia in Adult Non-HIV Disorders

    by Geoffrey S. Gilmartin, Henry Koziel

    Pneumocystis carinii pneumonia (PCP) remains a serious infection in the immunocompromised host (in the absence of HIV infection) and presents significant management and diagnostic challenges to ICU physicians. Non-HIV PCP is generally abrupt in onset, and follows a fulminate course with high rates of hospitalization, ICT admission, respiratory failure, and requirement for intubation. Mortality is generally high, especially if mechanical ventilation is required. Non-invasive ventilatory support may be considered, although the rapid progression to respiratory failure often necessitates intubation at the time of presentation. Bronchoscopy is often required to establish the diagnosis, and empirical antimicrobial treatment specifically targeted to P. carinii should be initiated while awaiting confirmation. Adjunctive corticosteroids may accelerate recovery, although their use has not yet been established in non-HIV PCP. For the ICU physicians to diagnose PCP, the non-specific presentation of an acute febrile illness and respiratory distress with diffuse pulmonary infiltrates requires a high clinical index of suspician, familiarity with clinical conditions associated with increased risk for PCP, and a low threshold for bronchoscopy to establish the diagnosis.


  • Alveolar Macrophages from Human Immunodeficiency Virus–Infected Persons Demonstrate Impaired Oxidative Burst Response to Pneumocystis carinii In Vitro

    by Henry Koziel, Xiuhong Li, Martine Y. K. Armstrong, Frank F. Richards, Richard M. Rose

    The alveolar macrophage (AM) oxidative burst response is an important component of microbicidal effector cell function against a variety of potential pathogens in the lungs, although the role against Pneumocystis carinii has not been fully investigated. The goals of this study were to characterize the P. carinii–mediated oxidative burst of AMs from healthy individuals, and to examine the oxidative burst of AMs from human immunodeficiency virus (HIV)–infected persons. For healthy individuals, the AM oxidative burst (measured as hydrogen peroxide [H2O2] production) increased in a time- and concentration-dependent manner in response to P. carinii or to the major surface glycoprotein of P. carinii, gp-A (0.01 to 10 μ g/ml), required physical contact of P. carinii with AMs, and was not dependent on organism viability. Enzymatic removal of the surface-associated molecules of P. carinii reduced the oxidative burst to 43% of control (P = 0.01). Blocking the AM mannose receptor reduced the P. carinii–mediated oxidative burst response to 37% of control (P = 0.01). Compared with AMs from healthy individuals, P. carinii–mediated H2O2 production was significantly reduced in AMs from asymptomatic HIV-positive (HIV + ) persons with CD4 + counts < 200 cells/mm3 (249 ± 43 relative fluorescence units [RFU] versus 130 ± 44 RFU; mean ± standard error of the mean, P = 0.038) and HIV + persons with active P. carinii pneumonia (78 ± 40 RFU; P = 0.014), but preserved for HIV + persons with CD4 + counts > 200 cells/mm3. Importantly, H2O2 production in response to phorbol myristate acetate or serum-opsonized zymosan particles was preserved in all groups studied. Thus, AM oxidative burst, mediated in part via P. carinii gp-A and AM mannose receptor may represent an important host response to P. carinii. A specific impairment of P. carinii–mediated AM oxidative burst in persons with advanced HIV infection may contribute to the pathogenesis of P. carinii pneumonia.


  • Management and Outcome Patterns for Adult Pneumocystis carinii Pneumonia, 1985 to 1995

    by Naresh G. Mansharamani, Robert Garland, David Delaney, Henry Koziel


  • Enhanced In Vivo Human Immunodeficiency Virus-1 Replication in the Lungs of Human Immunodeficiency Virus–Infected Persons with Pneumocystis carinii Pneumonia

    by Henry Koziel, Sue Kim, Christine Reardon, Xiuhong Li, Robert Garland, Paula Pinkston, Hardy Kornfeld

    The relationship of serum human immunodeficiency virus-1 (HIV-1) RNA levels to HIV-1 RNA levels in other compartments, such as the lungs, is not well characterized. The purpose of this study was to determine the viral burden of HIV-1 in the lungs by comparing HIV-1 RNA in cell-free bronchoalveolar lavage fluid (BALF) with that in serum. Specimens were examined from 77 HIV-seropositive adults (CD4+ cell counts: 0 to 700 cells/mm3; 48% receiving prescribed antiretroviral agents), comprising 43 asymptomatic individuals who were compared with 34 persons with active lung disease caused by Pneumocystis carinii (n = 26), bacteria (n = 3), Mycobacterium avium complex (n = 2), Nocardia sp. (n = 1), Aspergillus sp. (n = 1), or pulmonary Kaposi's sarcoma (n = 1). For serum HIV-1 RNA, the proportion of subjects with detectable levels and the mean values were similar for asymptomatic individuals and persons with active lung disease (85% versus 86%, respectively) (6.64 × 104 versus 1.81 × 105 HIV-1 RNA copies/ml; p = 0.13). In contrast, HIV-1 RNA in BALF was more often detected (16% versus 62%; p = 0.001), and mean values were higher (1.04 × 105 versus 3.31 × 106 HIV-1 RNA copies/ml; p = 0.032), in subjects with active lung disease than in asymptomatic subjects, independent of early or advanced clinical stages of HIV-related disease. For both study groups, HIV-1 RNA levels in BALF exceeded those in serum in 56% of cases by up to 66-fold, and did not correlate with local levels of tumor necrosis factor- α, granulocyte–macrophage colony-stimulating factor, or interleukin-16. HIV-1 proviral DNA in cells from BALF was detected in up to 86% of subjects, more frequently in persons with advanced HIV disease (p = 0.0496), and often involved > 10% of BALF cells, but did not correlate with HIV-1 RNA detected in BALF. These data provide evidence for active HIV-1 replication in the lungs. HIV-1 replication is compartmentalized relative to serum, may be restricted, is independent of HIV-1 proviral DNA and clinical stage of HIV, and may be influenced by pulmonary disease such as P. carinii pneumonia or by other local or lung-specific factors. The lungs represent a large reservoir for HIV-1, and may present a source of persistent HIV-1 replication even during periods of apparent clinical latency of HIV-1 infection. Koziel H, Kim S, Reardon C, Li X, Garland R, Pinkston P, Kornfeld H. Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus–infected persons with Pneumocystis carinii pneumonia.